NEO
NeoGenomics, Inc.
NEO has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
NEO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
NEO's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NEO PE Valuation
NEO has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
NEO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
NEO has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NEO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.29 | — |
| Q3 2026 | -$0.25 | +$0.63 |
| Q2 2026 | -$0.40 | +$0.41 |
| Q1 2026 | -$0.77 | -$0.16 |
| Q4 2025 | -$0.84 | -$0.22 |
| Q3 2025 | -$0.88 | -$0.27 |
| Q2 2025 | -$0.81 | -$0.19 |
| Q1 2025 | -$0.61 | +$0.05 |
| Q4 2024 | -$0.62 | +$0.08 |
NEO is still losing money, but far less than before: $0.25 per share over the past year, against $1.28 at its worst in late 2022.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over NEO on earnings quality, reporting a profit while its opponent remains loss making.
NEO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $209.3M | +11% |
| Q2 2026 | $201.7M | +11% |
| Q1 2026 | $186.7M | +11% |
| Q4 2025 | $190.2M | +11% |
| Q3 2025 | $187.8M | +12% |
| Q2 2025 | $181.3M | +10% |
| Q1 2025 | $168M | +7.5% |
| Q4 2024 | $172M | +11% |
NEO's revenue has grown year over year for 19 quarters in a row: $209M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.8% | +11 points |
| Q2 2026 | -4.8% | +21 points |
| Q1 2026 | -9.8% | +6.8 points |
| Q4 2025 | -7% | +3.6 points |
| Q3 2025 | -14% | -1.8 points |
| Q2 2025 | -26% | -13 points |
| Q1 2025 | -17% | +3 points |
| Q4 2024 | -11% | +1.2 points |
NEO's operating margin was −3.8% last quarter, up 11 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over NEO on profitability, with a higher operating margin.
NEO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$20.7M | -3724% |
| Q2 2026 | $11.7M | -16% |
| Q1 2026 | -$13.1M | +$16.7M |
| Q4 2025 | -$6.5M | -$4.7M |
| Q3 2025 | $570K | +$2.1M |
| Q2 2025 | $14M | +1621% |
| Q1 2025 | -$29.8M | +$1.7M |
| Q4 2024 | -$1.8M | -117% |
NEO has burned cash in most quarters: −$29M over the past year, against −$17M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over NEO on cash generation, producing positive trailing cash flow while its opponent burns cash.
NEO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.7% | -2.2M shares |
| 1 year | +0.1% | +172K shares |
| 3 years | +2.3% | +2.9M shares |
| 5 years | +4.9% | +6M shares |
| Available history | +19% | +20.8M shares |
NEO has 129M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over NEO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NEO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 14.9x | High |
| Q2 2021 | 14.7x | High |
| Q1 2021 | -6.3x | Net Cash |
| Q4 2020 | -2.7x | Net Cash |
| Q3 2020 | -4.0x | Net Cash |
| Q2 2020 | -9.4x | Net Cash |
| Q1 2020 | 0.5x | Very low |
| Q4 2019 | -1.6x | Net Cash |
NEO's net debt is about 15 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO has the edge over NEO on leverage, with a lower net debt burden relative to earnings.
NEO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.5 | Neutral |
| Stochastic | 38.7 | Neutral |
NEO's weekly RSI is 56 (neutral) and its Stochastic is 39 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NEO PE vs Healthcare Sector
| Metric | NEO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NEO has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NEO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $17.3 | 4.2% below |
| 20 week MA | $16.7 | 0.8% below |
| 50 week MA | $12.9 | 28% above |
| 100 week MA | $11.3 | 46% above |
| 200 week MA | $13.4 | 24% above |
NEO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
NEO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.8 | $55.4 | +86% |
| 2021 | $55.4 | $34.3 | -38% |
| 2022 | $34.3 | $9.17 | -73% |
| 2023 | $9.17 | $16.2 | +76% |
| 2024 | $16.2 | $16.8 | +4% |
| 2025 | $16.8 | $12.3 | -27% |
| 2026 YTD | $12.3 | $16.5 | +35% |
NEO has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.